Verily Life Sciences LLC

California Institute of Technology

Evotec Ag

Renovis, Inc.

Lycera Corporation

Evotec (us) Inc.

Second Genome, Inc.

Evotec Inc.

Zhan Wang

John Kincaid

Stephen Morton

Carl J Kaub

Yeyu Cao

Sumithra Gowlugari

Nicole Peck

Michael G Kelly

Frances H Arnold

Kimberly Kam

Jared C Lewis

Pedro S Coelho

Eric M Brustad

Yunfeng Fang

Zhi-Liang Wei

Timothy Tordella Ruckh

William L Thomas

Gary D Glick

Thomas Daniel Aicher

Matthew Duncton

Arthur Glenn Romero

Peter Laurence Toogood

Chad A VanHuis

Carl Kaub

Chad A Van Huis

Donogh John Roger O'Mahony

Matthew N Mattson

Karin Ann Stein

Matthew Alexander James Duncton

Jianhua He, Legal Representative

Erik Krogh-Jespersen

Donogh O'MAHONY

William David Thomas

Provided herein are encapsulated liposomes comprising a lipid bilayer, a first polyethylene glycol (PEG) corona, a targeting molecule and a second PEG corona. The second, encapsulating PEG corona can be reversibly linked to the first PEG corona. Also provided are pharmaceutical compositions comprising the encapsulated liposomes and methods of treating a subject with a disease characterized by production of reactive oxygen species (ROS) with the compositions. Also provided are methods of making the encapsulated liposomes disclosed herein.

ROS-responsive liposomes for specific targeting

An analyte-sensitive substance is provided that has an optical property related to the concentration of an analyte. The analyte-sensitive substance includes an ionophore or other substance configured to provide a local pH, within the analyte-sensitive substance, that is related to the concentration of the analyte proximate the analyte-sensitive substance. The analyte-sensitive substance further includes a pH-sensitive fluorophore that increases or decreases its intrinsic fluorescence intensity with the local pH across a specified range of pH values. The analyte-sensitive substance further includes a pH-sensitive quencher configured to increase the slope of the change of fluorescence intensity of the pH-sensitive fluorophore across the specified range of pH values. The analyte-sensitive substance may further include an ionic additive configured to adjust the local pH such that the specified range of pH values corresponds to a range of analyte concentration values of interest.

Method for increasing sensor resolution by spectrally stacking responsive dyes

Provided herein are liposomal vesicles comprising at least a first lipid bilayer and a second lipid bilayer, and a plurality of crosslinkages between the first lipid bilayer and the second lipid bilayer, wherein the plurality of crosslinkages comprise boronic ester or thioketal bonds. Also provided are pharmaceutical compositions comprising the liposomal vesicles described herein and a pharmaceutically acceptable excipient. Also provided are methods of making and using the liposomal vesicles. Thus, a method of treating a subject with a disease comprising administering to the subject a pharmaceutical composition comprising the liposomal vesicles is described herein. Methods of making multilamellar liposomal vesicles responsive to reactive oxygen species are also provided.

ROS-responsive multilamellar liposomal vesicles for targeting inflammatory macrophages

The present invention provides methods for catalyzing the conversion of an olefin to any compound containing one or more cyclopropane functional groups using heme enzymes. In certain aspects, the present invention provides a method for producing a cyclopropanation product comprising providing an olefinic substrate, a diazo reagent, and a heme enzyme; and admixing the components in a reaction for a time sufficient to produce a cyclopropanation product. In other aspects, the present invention provides heme enzymes including variants and fragments thereof that are capable of carrying out in vivo and in vitro olefin cyclopropanation reactions. Expression vectors and host cells expressing the heme enzymes are also provided by the present invention.

Cytochrome P450 BM3 enzyme variants for preparation of cyclopropanes

A composition and methods of use and preparation are provided. The composition may comprise a magnetic nanoparticle comprising: a passivation layer; and at least one unique entity that is attached to the magnetic nanoparticle. For example, the composition may include a magnetic nanoparticle and an antibody attached to the magnetic nanoparticle. Such magnetic nanoparticle architecture can provide treatment by, and screening of, nanoparticles functionalized with various functional species.

Passivated magnetic nanoparticles for cell targeting and methods of preparation and use

Disclosed herein are methods for producing bi-directionally crosslinked liposomes. The methods include the steps of: providing a lipid composition comprising a plurality of reactive lipids, wherein each of the reactive lipids comprises a reactive hydrophobic group, a reactive hydrophilic group, or a reactive hydrophilic group and a reactive hydrophobic group; forming an un-crosslinked liposome comprising the reactive lipids; and crosslinking at least a portion of the reactive hydrophobic groups or the reactive hydrophilic groups; thereby producing the bi-directionally crosslinked liposomes. Bi-directionally crosslinked liposomes and methods for delivering therapeutic and/or diagnostic agents to subjects using the liposomes are also described.

Bi-directionally crosslinked liposomes and method of making same

ROS&#x2014;responsive liposomes for specific targeting

In vivo and in vitro olefin cyclopropanation catalyzed by heme enzymes

The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting ROR&#x3b3; activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroquinoline and related compounds are provided.

N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of ROR&#x3b3; activity and the treatment of disease

Compounds are provided according to formula 1: where A, B, W, X', L, R, R, R, and m&#x2032; are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.

Amide compounds, compositions and uses thereof

Growing community of inventors

San Jose, CA, United States of America

Zhan Wang